DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Summary for Patent: 5,173,295
|Title:||Method of enhancing the regeneration of injured nerves and adhesive pharamaceutical formulation therefor|
|Abstract:||The regeneration of injured nerves is enhanced by supplying collagenase to the zone of injury of the nerve. Growth of nerve sprouts over the zone of injury is aided by the presence of effective amounts of collagenase during the regeneration process. If the nerve has been severed, collagenase is supplied to the ends of the proximal and distal stumps. A nerve graft may be interposed between the stumps. Natural fibrin has been used as glue to join nerve stumps, and collagenase is effective when used in admixture with fibrin.|
|Inventor(s):||Wehling; Peter (Monheim, DE)|
|Assignee:||Advance Biofactures of Curacao, N.V. (Curacao, AN)|
|Patent Claims:||1. A method of enhancing the regeneration of injured nerves which comprises administering an effective amount of collagenase to the zone of injury of the nerve during the regeneration
2. A method according to claim 1 wherein the nerve has been severed and collagenase is administered to the ends of the proximal and distal stumps.
3. A method according to claim 2 wherein fibrin containing collagenase is used as adhesive for the stumps.
4. A method according to claim 3 wherein the ends are sutured.
5. A method according to claim 4 wherein the sutured region is coated with a fibrin and collagenase mixture.
6. A method according to claim 1 wherein injury has resulted in neuroma in continuity.
7. A method according to claim 1 wherein the stumps of individual served fascicles of fascicle groups are separately co-apted.
8. A method according to claim 2 wherein a nerve graft is interposed between the stumps.
9. A method according to claim 8 wherein interfascicular nerve grafts are employed.
10. A method according to claim 1 wherein collagenase is supplied in a pharmaceutically acceptable medium containing about 200 to 2,500 ABC units of collagenase/ml.
11. A method according to claim 10 wherein the medium comprises normal saline.
12. A method according to claim 1 wherein collagenase is supplied in a pharmaceutically acceptable medium containing about 500 to 1,000 ABC units of collagenase/ml.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Smith And Nephew||SANTYL||collagenase||OINTMENT;TOPICAL||101995||001||1965-06-04||⤷ Free Forever Trial||Advance Biofactures of Curacao, N.V. (Curacao, AN)||2039-02-26||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.